- Home
- RTO vs RPRX Comparison
RTO vs RPRX Comparison
Compare RTO & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RTO
- RPRX
- Stock Information
- Founded
- RTO 1925
- RPRX 1996
- Country
- RTO United Kingdom
- RPRX United States
- Employees
- RTO N/A
- RPRX N/A
- Industry
- RTO Business Services
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- RTO Consumer Discretionary
- RPRX Health Care
- Exchange
- RTO Nasdaq
- RPRX Nasdaq
- Market Cap
- RTO 12.2B
- RPRX 14.2B
- IPO Year
- RTO N/A
- RPRX 2020
- Fundamental
- Price
- RTO $23.08
- RPRX $32.60
- Analyst Decision
- RTO Hold
- RPRX Strong Buy
- Analyst Count
- RTO 1
- RPRX 4
- Target Price
- RTO N/A
- RPRX $42.50
- AVG Volume (30 Days)
- RTO 1.1M
- RPRX 5.5M
- Earning Date
- RTO 03-26-2025
- RPRX 05-08-2025
- Dividend Yield
- RTO 2.54%
- RPRX 2.71%
- EPS Growth
- RTO N/A
- RPRX N/A
- EPS
- RTO 0.15
- RPRX 1.91
- Revenue
- RTO $6,805,463,398.00
- RPRX $2,263,576,000.00
- Revenue This Year
- RTO $6.81
- RPRX $31.56
- Revenue Next Year
- RTO $3.82
- RPRX $5.94
- P/E Ratio
- RTO $30.34
- RPRX $17.05
- Revenue Growth
- RTO 1.14
- RPRX N/A
- 52 Week Low
- RTO $19.60
- RPRX $24.05
- 52 Week High
- RTO $34.07
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- RTO 54.69
- RPRX 54.58
- Support Level
- RTO $21.68
- RPRX $32.02
- Resistance Level
- RTO $22.53
- RPRX $32.31
- Average True Range (ATR)
- RTO 0.82
- RPRX 0.97
- MACD
- RTO 0.18
- RPRX 0.12
- Stochastic Oscillator
- RTO 90.39
- RPRX 97.84
About RTO Rentokil Initial plc
Rentokil Initial is the largest global provider of route-based pest-control and commercial hygiene services, operating in 83 countries. The group also offers a range of specialist route-based services including office and commercial space plant care, property care, and workwear rentals. The group has a diverse client base that includes global food producers, hotel chains, industrial goods businesses, restaurants, and individual residential customers.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.